Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
已完结
10
由 123 发布于 2026/8/10 16:46:42
DOI:10.1016/S1470-2045(21)00630-6
作者：Qing Zhou,?Ming Chen,?Ou Jiang,?Yi Pan,?Desheng Hu,?Qin Lin,?Gang Wu,?Jiuwei Cui,?Jianhua Chang,?Yufeng Cheng,?Cheng Huang,?Anwen Liu,?Nong Yang,?Youling Gong,?Chuan Zhu,?Zhiyong Ma,?Jian Fang,?Gongya
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1016/S1470-2045(21)00630-6
作者：Qing Zhou,?Ming Chen,?Ou Jiang,?Yi Pan,?Desheng Hu,?Qin Lin,?Gang Wu,?Jiuwei Cui,?Jianhua Chang,?Yufeng Cheng,?Cheng Huang,?Anwen Liu,?Nong Yang,?Youling Gong,?Chuan Zhu,?Zhiyong Ma,?Jian Fang,?Gongya
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1016/S1470-2045(21)00630-6
Elsevier
其它数据库
京公网安备 11010802042870号
